Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Personalized cancer vaccines are having a moment. Moderna's mRNA vaccine intismeran, paired with pembrolizumab, became the first personalized cancer vaccine to hit its primary endpoint in a phase 3 trial for high-risk melanoma. Meanwhile, a separate viral vector-based vaccine, TG4050, showed zero recurrences in vaccinated head and neck cancer patients vs. three in the surveillance group — though experts say more data is still needed.
Personalized cancer vaccines are gaining serious momentum, with new clinical data from two distinct approaches making waves in oncology. Moderna and Merck's mRNA vaccine intismeran, combined with the checkpoint inhibitor pembrolizumab, met its primary endpoint of recurrence-free survival in the phase 3 INTerpath-001 trial — a first for any personalized mRNA cancer vaccine. The trial enrolled over 1,100 patients with completely resected, high-risk melanoma, with each vaccine individually designed to target up to 34 tumor-specific neoantigens.
On a separate front, Transgene's TG4050 — a viral vector-based vaccine — showed encouraging results in a phase 1 trial for HPV-negative head and neck squamous cell carcinoma. None of the 16 vaccinated patients experienced recurrence after a median 30-month follow-up, compared to 3 of 16 in the surveillance group. T-cell responses were detected in nearly three-quarters of vaccinated patients and persisted beyond a year in some cases.
Key Takeaways:
Why it matters: These results mark a meaningful step toward individualized cancer treatment, but the path to widespread clinical use still requires solving complex manufacturing, biomarker, and delivery challenges.
